ResMed (RMD) Given Media Sentiment Rating of 0.19
Media stories about ResMed (NYSE:RMD) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ResMed earned a news impact score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 45.3885230859198 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Zacks: Analysts Anticipate ResMed Inc. (RMD) to Post $0.76 EPS (americanbankingnews.com)
- ResMed CHESS : Elects Karen Drexler to Its Board of Directors (4-traders.com)
- ResMed Elects Karen Drexler to Its Board of Directors (finance.yahoo.com)
- Fisher & Paykel says UK court rules rival Resmed’s patent is invalid (RMD, FPH) (markets.businessinsider.com)
- ResMed : Says Considers Appeal On U.K. Case With Fisher & Paykel (4-traders.com)
RMD has been the subject of a number of recent research reports. Credit Suisse Group lowered ResMed from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 8th. Zacks Investment Research lowered ResMed from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Northland Securities reissued a “sell” rating and issued a $55.00 target price on shares of ResMed in a research note on Friday, October 27th. Jefferies Group LLC reissued a “sell” rating and issued a $56.00 target price on shares of ResMed in a research note on Thursday, October 12th. Finally, BMO Capital Markets boosted their target price on ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research note on Wednesday, August 2nd. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $67.57.
ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company had revenue of $523.66 million for the quarter, compared to the consensus estimate of $506.08 million. During the same quarter in the previous year, the business earned $0.62 EPS. ResMed’s revenue was up 12.5% compared to the same quarter last year. equities research analysts anticipate that ResMed will post 3 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 14th. Investors of record on Thursday, November 9th will be issued a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $1.40 dividend on an annualized basis and a yield of 1.65%. ResMed’s dividend payout ratio is presently 56.68%.
In other ResMed news, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $84.50, for a total transaction of $105,625.00. Following the transaction, the chief financial officer now owns 71,772 shares in the company, valued at approximately $6,064,734. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 118,392 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $82.70, for a total value of $9,791,018.40. Following the transaction, the director now owns 306,615 shares in the company, valued at approximately $25,357,060.50. The disclosure for this sale can be found here. Insiders have sold a total of 201,234 shares of company stock worth $16,339,637 in the last quarter. Company insiders own 1.77% of the company’s stock.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Stock Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related stocks with our FREE daily email newsletter.